Coya Therapeutics, Inc. (COYA)
NASDAQ:COYA
Want to see COYA full AI Analyst Report?
COYA Stock Chart & Stats
$4.78
-$0.10(-1.62%)
At close: 4:00 PM EST
$4.78
-$0.10(-1.62%)
Day’s Range― - ―
52-Week Range$3.71 - $7.75
Previous CloseN/A
Volume16.99K
Average Volume (3M)266.35K
Market Cap
$95.47M
Enterprise Value$21.26M
Total Cash (Recent Filing)$46.82M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.24
Next Earnings
May 07, 2026EPS Estimate
-0.42Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.34
Shares Outstanding23,457,184
10 Day Avg. Volume216,274
30 Day Avg. Volume266,345
Financial Highlights & Ratios
PEG Ratio-0.15
Price to Book (P/B)2.26
Price to Sales (P/S)12.21
P/FCF Ratio-9.04
Enterprise Value/Market Cap0.22
Enterprise Value/Revenue2.68
Enterprise Value/Gross Profit2.68
Enterprise Value/Ebitda-1.05
Forecast
1Y Price Target
$16.25Price Target Upside239.96% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-1.62
Revenue Forecast (FY)$1.92M
Bulls Say, Bears Say
Bulls Say
Clinical MilestonesCompletion of enrollment in the lead ALS trial and initiation of a double‑blind phase two study create defined clinical milestones that could lift the stock if biomarker and placebo‑controlled results confirm target engagement.
Manufacturing And Financing ReadinessA securities purchase agreement plus plans to tech transfer and scale manufacturing for low‑dose IL‑2 signal financial support and manufacturing readiness that could accelerate commercial preparation after successful trials.
Regulatory Approval PathwayFDA acceptance of an Investigational New Drug application for COYA 302 enables a company‑driven U.S. clinical program in frontotemporal dementia and paves the way for larger controlled trials.
Bears Say
Clinical Development RiskHigh historical failure rates in ALS drug development highlight the material risk that COYA‑302 could face clinical setbacks in later‑stage trials, which would negatively affect the stock.
Data MaturitySeveral investigator‑led studies involved small patient numbers and likely lacked sufficient duration to demonstrate durable, disease‑modifying effects, so current signals remain preliminary.
Evidence RobustnessThe frontotemporal dementia readout came from a small, single‑center cohort with wide variability, limiting confidence in the findings and increasing the need for replication in larger studies.
Coya Therapeutics, Inc. News
COYA FAQ
What was Coya Therapeutics, Inc.’s price range in the past 12 months?
Coya Therapeutics, Inc. lowest stock price was $3.71 and its highest was $7.75 in the past 12 months.
What is Coya Therapeutics, Inc.’s market cap?
Coya Therapeutics, Inc.’s market cap is $95.47M.
When is Coya Therapeutics, Inc.’s upcoming earnings report date?
Coya Therapeutics, Inc.’s upcoming earnings report date is May 07, 2026 which is in 7 days.
How were Coya Therapeutics, Inc.’s earnings last quarter?
Coya Therapeutics, Inc. released its earnings results on Mar 16, 2026. The company reported -$0.34 earnings per share for the quarter, missing the consensus estimate of -$0.273 by -$0.067.
Is Coya Therapeutics, Inc. overvalued?
According to Wall Street analysts Coya Therapeutics, Inc.’s price is currently Undervalued.
Does Coya Therapeutics, Inc. pay dividends?
Coya Therapeutics, Inc. does not currently pay dividends.
What is Coya Therapeutics, Inc.’s EPS estimate?
Coya Therapeutics, Inc.’s EPS estimate is -0.42.
How many shares outstanding does Coya Therapeutics, Inc. have?
Coya Therapeutics, Inc. has 23,457,184 shares outstanding.
What happened to Coya Therapeutics, Inc.’s price movement after its last earnings report?
Coya Therapeutics, Inc. reported an EPS of -$0.34 in its last earnings report, missing expectations of -$0.273. Following the earnings report the stock price went down -0.662%.
Which hedge fund is a major shareholder of Coya Therapeutics, Inc.?
Currently, no hedge funds are holding shares in COYA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Coya Therapeutics, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$16.25 (239.96% Upside)
$16.25 (239.96% Upside)
Crowd Wisdom
Negative
Last 7 Days ▼ 1.0%
Last 30 Days >0.1%
Last 30 Days >0.1%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-32.31%
12-Months-Change
Fundamentals
Return on Equity
-64.33%
Trailing 12-Months
Asset Growth
12.63%
Trailing 12-Months
Company Description
Coya Therapeutics, Inc.
Coya Therapeutics, Inc., a clinical-stage biotechnology company, develops proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It is developing COYA 101, an autologous regulatory T-cell product candidate that has completed Phase 2a clinical trial for use in the treatment of Amyotrophic Lateral Sclerosis. The company's product candidates in IND-enabling studies include COYA 301, a Treg-enhancing biologic for use in the treatment of Frontotemporal Dementia; and COYA 302, a biologic combination for subcutaneous and/or intravenous administration intended to enhance Treg function while depleting T effector function and activated macrophages for use in the treatment of neurodegenerative and autoimmune diseases. It is also developing COYA 201, an allogeneic Treg exosome product candidate that is in preclinical stage for use in the treatment of neurodegenerative, autoimmune, and metabolic diseases; and COYA 206, an antigen directed Treg-derived exosome product candidate, which is in discovery stage. The company was incorporated in 2020 and is headquartered in Houston, Texas.
COYA Stock 12 Month Forecast
Average Price Target
$16.25
▲(239.96% Upside)
Technical Analysis
Ownership Overview
4.42% Insiders
4.12% Mutual Funds
0.01% Other Institutional Investors
87.41% Public Companies and
Individual Investors